Boehringer Ingelheim and Eli Lilly Present Results of Jardiance (empagliflozin) in P-III EMPEROR-Preserved Trial for HFpEF at ASN Kidney Week 2021

Shots:

• The P-III EMPEROR-Preserved trial evaluates the safety & efficacy of Jardiance (10mg, qd) vs PBO in 5,988 patients with chronic HFpEF with/out diabetes
• The results showed a reduction in risk for composite 1EPs of CV death or hospitalization for HF & slowed kidney function decline in adults with HF with LVEF. The new prespecified sub-analysis showed consistent cardio-renal benefits in an overall population & improved CV outcomes, was well tolerated
• The therapy has previously received FTD from the US FDA to reduce the risk of CV death & hospitalization for HF & is approved for HFrEF with/out diabetes in the EU & US. The companies plan for global regulatory submissions for HFpEF in 2021

Click here to­ read the full press release/ article | Ref: Eli Lilly | Image:  Eli Lilly